An investigation on behalf of current long term investors in Albany Molecular Research, Inc. (NASDAQ:AMRI) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ:AMRI stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 08/30/2016 --Certain directors of Albany Molecular Research are under investigation over potential wrongdoing. The investigation was announced on behalf of current long-term investors in NASDAQ:AMRI concerning potential breaches of fiduciary duties by certain directors and officers of Albany Molecular Research.

Investors who are current long term investors in Albany Molecular Research, Inc. (NASDAQ:AMRI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm for current long term investors in NASDAQ:AMRI stocks follows a lawsuit filed against Albany Molecular Research, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:AMRI stocks, concerns whether certain Albany Molecular Research directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges that the defendants violated Federal Securities Laws by issuing certain allegedly materially false and misleading statements about its business and financial prospects.

On November 5, 2014, Albany Molecular Research, Inc. announced its third quarter 2014 results. Albany Molecular Research, Inc reported that its third quarter Revenue rose from $60.75 million in 2013 to $62.47 million in 2014, while its third quarter 2013 Net Income of $3.7 million declined to a third quarter 2014 Net Loss of $8.64 million. Among other things, Albany Molecular Research, Inc also adjusted its financial outlook for the fully year 2014. Albany Molecular Research, Inc said it now expects full year contract revenue is expected to be between $253 and $261 million, adjusted EBITDA between $50 and $52 million, and adjusted diluted EPS is expected to be between $0.67 and $0.73.

Those who purchased shares of Albany Molecular Research, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com